by Stacey Hawkins | Sep 7, 2017 | Immunotherapies
THE FLASH OF THE FIRST CAR-T Last week’s much anticipated FDA approval of the first chimeric antigen receptor T-cell (CAR-T) therapy for acute lymphocytic leukemia hails as the first gene therapy on the US market. Classified as a “cell-based gene therapy,” Novartis’... 
by Stacey Hawkins | Jan 19, 2017 | Immunotherapies
Understanding CAR-T Safety Chimeric antigen receptor therapy (CAR-T) is our top technology pick of 2016, blazing trails in drug development with its innovative approach of using engineered immune cells to fight cancer. Despite its success in clinical trials, safety...
